Media about us

  • 08 September 2017

    New 30-minute STI test allows just one clinic trip

    New 30-minute STI test allows just one clinic trip

    Helen Clark / Gears of Biz

    A new speedy test will mean that for the first time ever patients with common sexually-transmitted infections will be able to get their diagnosis and treatment in one clinical visit. The test works by placing a swab or a small amount of urine into a test cartridge, which is then inserted into the diagnostic machine, which has been designed by innovation firm Atlas Genetics Ltd.

  • 07 September 2017

    Roche to up Russian Gazyva supply through local fill/finish deal

    Roche to up Russian Gazyva supply through local fill/finish deal

    Dan Stanton / BioPharma Reporter.com

    Local manufacturer Pharmstandard will make the finished dosage form of Roche’s monoclonal antibody Gazyva (obinutuzumab) at its site in Ufa. The policy has driven most multinationals to sign contracts with domestic drugmakers and invest in local joint ventures. Pfizer broke ground on a facility with NovaMedica in Kaluga in May, GSK formed a JV with Binnopharm in 2011, while AstraZeneca , Novartis and Novo Nordisk have all invested in Russian production facilities.

  • 17 August 2017

    Prostate Cancer: Epic Sciences AR-V7 Test

    Prostate Cancer: Epic Sciences AR-V7 Test

    OncLive

    Insights From: Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine; Andrew J. Armstrong, MD, MSc, Duke Cancer Center; Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center share their views on the Epic Sciences AR-V7 test in development for prostate cancer.

  • 29 June 2017

    Syndax Locks In To Tumor Escape

    Syndax Locks In To Tumor Escape

    Seeking Alpha

    Syndax (NASDAQ:SNDX) is a $315 million market cap company focused on developing a pipeline of innovative combination therapies for cancer. The company's lead product is Entinostat, which was granted Breakthrough Therapy Designation by FDA for its Phase 2b clinical trial in advanced hormone receptor positive (Estrogen Receptor positive, ER+) breast cancer. The impact of Breakthrough Therapy Designation on biotechnology stocks has been previously described here by Strong Bio and is worth a read. The company has a host of impressive partnerships for its clinical trials, including Merck (NYSE:MRK) for a combinatory non-small cell lung cancer (NSCLC) and melanoma therapy, Genentech/Roche (OTCQX:RHHBY) for triple-negative breast cancer (TNBC), and Pfizer (NYSE:PFE) and Merck in Germany for ovarian cancer.

  • 16 June 2017

    LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

    LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

    LA BioMed

    The Medical Mycology Society of the Americas has honored John E. “Jack” Edwards, Jr., MD, an LA BioMed lead researcher, as the winner of the 2017 Rhoda Benham Award. The award is given “to an individual from the Americas for continuous outstanding or meritorious contributions to medical mycology,” which is the study of fungal diseases. Dr. Edwards, together with his group of colleagues, founded NovaDigm Therapeutics to translate the three decades of research into products that will prevent or treat serious infectious diseases. 

  • 15 June 2017

    OD reports practices success with corneal inlay

    OD reports practices success with corneal inlay

    Jeffrey M. Augustine, OD / Healio

    The keys to success with the Raindrop Near Vision Inlay are patient selection and evaluation of ocular surface, centration and inflammation, he said. The use of corneal inlays for the surgical correction of presbyopia is an exciting new technology for optometry, ophthalmology and, especially, for the presbyopic patient.

  • 13 June 2017

    Pfizer eyes building another plant in Russia

    Pfizer eyes building another plant in Russia

    ThePharmaLetter

    US pharma giant Pfizer (NYSE: PFE) is considering building another manufacturing plant in Russia during the next several years, which is expected to be located in the Tatarstan Republic, one of Russia’s richest and economically developed regions. In addition on May 30, Pfizer officially started building its first Russian plant in the Kaluga Vorsino technopark, which takes place in cooperation with its local partner NovaMedica.

  • 05 June 2017

    Russian partnerships: Pfizer and NovaMedica break ground on aseptic plant

    Russian partnerships: Pfizer and NovaMedica break ground on aseptic plant

    Dan Stanton / InPharma Technologist

    Pfizer and NovaMedica have broken ground on a manufacturing facility in Kaluga set to supply the Russian market with sterile injectable drugs. The ceremony this week comes five months after global pharma firm Pfizer announced it had completed the transfer of the rights and technologies for the production of over.
  • 05 June 2017

    The three factors crucial to effectiveness in healthcare

    The three factors crucial to effectiveness in healthcare

    SPIEF-2017. Panel discussion "The three factors crucial to effectiveness in healthcare". “The problem and task is to boost the system’s performance within the budget available for now. That does not mean the system needs no more money, that means spending must be efficient,” said Leonid Melamed, Chairman of the Board of Directors, Team Drive.

  • 01 June 2017

    Plant to produce Pfizer sterile injectables for Russia gets under way

    Plant to produce Pfizer sterile injectables for Russia gets under way

    Eric Palmer / Fierce Pharma

    Russia's NovaMedica is building a new sterile injectables plant in the Kaluga region where it will produce 30 of Pfizer’s sterile injected generic meds for the local market.

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news